Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 1/20 | 0.67 |
| ▸ | F12 | P00748 | 1/20 | 0.67 |
| ▸ | F11 | P03951 | 1/20 | 0.67 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.67 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.67 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.67 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.67 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | C1S | P09871 | 13/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TARS1 | P26639 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26771033 | 0.89 | PLG (0.53) | PLGF12F11KLKB1PRSS1 | |
| SCHEMBL24252503 | 0.78 | PLG (0.67) | PLGF12F11KLKB1PRSS1 | |
| SCHEMBL30452858 | 0.78 | PLG (0.52) | PLGF12F11KLKB1PRSS1 | |
| SCHEMBL24252259 | 0.76 | DHFR (0.42) | PLGF12F11KLKB1PRSS1 | |
| SCHEMBL24252733 | 0.75 | PLG (0.56) | PLGF12F11KLKB1PRSS1 | |
| SCHEMBL30451657 | 0.75 | PLG (0.56) | PLGF12F11KLKB1PRSS1 | |
| Formic Acid SCHEMBL25257239 | 0.72 | DHFR (0.39) | PLGF12F11KLKB1PRSS1 | |
| SCHEMBL24252257 | 0.72 | PLG (0.52) | PLGF12F11KLKB1PRSS1 | |
| SCHEMBL24252273 | 0.71 | PLG (0.51) | PLGF12F11KLKB1PRSS1 | |
| Hydrochloric Acid SCHEMBL30467690 | 0.71 | PLG (0.51) | PLGF12F11KLKB1PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2024-04-04 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| CN-116947903-A | Inhibitors of complement factors and uses thereof | 安尼艾克松股份有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-116261564-A | Inhibitors of complement factors and uses thereof | 安尼艾克松股份有限公司 | 2023-06-13 | — | — | CN | disclosed |
| EP-4185592-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | Annexon, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2022-02-17 | — | — | US | disclosed |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | PLG 260/4885F12 29/4885F11 117/4885 |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | PLG 260/4885F12 29/4885F11 117/4885 |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | CFB, CFH, C9 | PLG 260/4885F12 29/4885F11 117/4885 |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | SSB, UACA, CFH | PLG 3106/4885F12 149/4885F11 195/4885 |
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFH, CFB, C5 | PLG 1433/4885F12 38/4885F11 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.